Published in:
01-08-2021 | Sudden Cardiac Death | Editorial
How to best appreciate the possible clinical role of cardiac 123I-mIBG scintigraphy in heart failure patients: Trying not to get lost while going in the right direction!
Authors:
H. J. Verberne, MD, PhD, D. O. Verschure, MD, PhD
Published in:
Journal of Nuclear Cardiology
|
Issue 4/2021
Login to get access
Excerpt
Cardiac
123I-
mIBG scintigraphy, a non-invasive imaging technique to assess cardiac sympathetic activity, has been shown to be of clinical value, especially for the assessment of prognosis in patients with chronic heart failure (CHF).
1,
2 The semi-quantification of the images is essential to differentiate normal and abnormal cardiac sympathetic activity and thereby identify respectively the low and high risk groups. In the ADMIRE-HF study (
n = 961), so far the largest prospective multicenter study addressing the prognostic value of cardiac
123I-
mIBG scintigraphy, a predefined LEHR (low energy high resolution) collimator-derived late heart-to-mediastinum (H/M) ratio < 1.6 was shown to be an independent predictor of heart failure progression, cardiac death, and arrhythmia.
1 A pooled individual patient data meta-analysis showed that, in CHF patients (
n = 636), the late H/M ratio is not only useful as a dichotomous predictor of events (high vs low risk) but also has prognostic implication over the full range of the outcome value for all event categories except arrhythmias.
2 …